InCred Capital booked profits in Adani Port and exited Cipla due to margin concerns, while introducing Camlin Life Science, anticipating stabilization and benefits from anti-dumping duties. They remain neutral on IT and consumer staples, favoring autos and high-end consumption plays like Ethos and TCPL Packaging. Despite tepid Nifty 50 earnings growth, mid and smallcaps show promise.